Developer docs
API playgroundTry for free, no card

Search company profiles

Satio

Full company profile

uuid0003jri

Namestring
Satio
Legal namestring
satio, Inc.
Websiteurl
satiopatch.com
Company typeenum
Private
Founded yearint
2021
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
patch-based diagnostics, microneedle drug delivery, blood collection devices, intradermal delivery, medical device patches
Industry2 codes
PRIMARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAO
DTx/SaMD Deployment, Integration & Reimbursement Enablement
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code1 code
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Point-of-Care Medical Devices
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Drug Delivery Patches (SatioRx)
TypeHardware Sales
Description

Sale of reusable applicators and disposable microneedle patches to pharmaceutical partners and healthcare providers. The reusable device with disposable components creates recurring consumable revenue.

satiopatch.com
2Diagnostic Patches (SatioDx)
TypeHardware Sales
Description

Sale of diagnostic patches incorporating lateral flow assays and biosensor technology to diagnostic and consumer healthcare companies.

satiopatch.com
3Blood Collection Patches (SatioDot/SatioDraw)
TypeHardware Sales
Description

Sale of blood collection patches to CLIA labs and diagnostic companies for laboratory developed tests. Revenue from patch sales to laboratory partners.

satiopatch.com
4Licensing and Partnership Revenue
TypeLicensing Royalties
Description

Technology licensing to pharmaceutical companies for drug delivery applications and to diagnostic companies for platform integration. Strategic partnerships with BARDA and ARPA-H provide non-dilutive funding.

satiopatch.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1SatioDot
Description

Dried Blood Spot (DBS) collection patch for consumer-based sample collection for CLIA labs with laboratory developed tests.

satiopatch.com
+3 more records
Core offering1 text field

Satio develops patch-based platforms for at-home blood collection, point-of-care diagnostics, and intradermal drug and vaccine delivery. The portfolio comprises SatioRx (reusable applicator with disposable hollow microneedle arrays for remote-controlled drug delivery), SatioDx (adhesive patch integrating blood draw with lateral flow/biosensor readouts), SatioDot (dried blood spot collection patch for CLIA lab testing), and SatioDraw (whole blood collection patch of approximately 100uL for genomic and clinical tests).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Increased payload delivery 2.5-5x compared to typical intradermal delivery
+5 more records
Product overview1 text field

Satio develops a portfolio of four distinct patch-based platforms addressing diagnostics and drug delivery. SatioRx™ is a reusable drug delivery patch with microneedle arrays for intradermal/subcutaneous administration. SatioDx™ provides point-of-care blood draw and diagnosis with on-device results. SatioDot™ enables dried blood spot collection for lab-based testing. SatioDraw™ handles whole blood collection for CLIA laboratory testing. Together, these platforms enable decentralized healthcare with at-home diagnostics and drug delivery without needles or professional administration.

Product and service4 records
1SatioRx
CategoryDrug Delivery Platform
Description

Reusable drug delivery platform with adhesive patch-based microneedle technology enabling stable and controlled intradermal or subcutaneous delivery of liquid medicines. Combines a motor-controlled applicator with disposable hollow non-dissolving microneedle elements, NFC connectivity, and telehealth integration for remote activation and monitoring, supporting 1mL to 5mL drug cartridges and viscosities up to 100cP.

2SatioDx
CategoryPoint-of-Care Diagnostic Device
Description

Consumer-based blood draw and diagnostic patch allowing users to collect blood and receive test results directly on the device. Available in Manual and Digital versions, with integrated lateral flow assays and biosensor technology, a lancet port with 130 microliter collection capacity, vacuum-assisted blood draw, and onboard result readout for multi-analyte screening.

3SatioDot
CategoryBlood Collection Patch
Description

Dried blood spot (DBS) collection patch enabling simple, painless, and low-cost consumer-based self-collection for clinical laboratory testing with easy transport and storage, designed for CLIA labs running laboratory developed tests.

4SatioDraw
CategoryBlood Collection Patch
Description

Whole blood collection patch allowing simple consumer-based collection of 100 microliters (range 50–150 microliters) for CLIA labs running laboratory developed tests, supporting diagnosis and whole genome sequencing without fingerstick or mess.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-14
Description

Strategic collaboration to integrate Nanowear's AI-based SimpleSense biomarker platform with Satio's blood draw diagnostics and drug delivery patches. Combines in vivo cardiometabolic biomarkers with in vitro blood diagnostics in a single digital app. Targets $55 billion biopharma clinical research market and $200 billion telehealth segment. First-of-its-kind combination of blood/genotype biomarkers with cardiometabolic physiological data.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-18
Description

Contract partnership with Biomedical Advanced Research and Development Authority's Division of Research, Innovation and Ventures (DRIVe) to develop novel patch-based ebolavirus diagnostic. Combines Satio's patch-based blood collection with Institut Pasteur de Dakar's immunoassay. Goal to create low-cost, rapid diagnostic deployable by community health workers in remote settings.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-08-23
Description

Partnership to jointly improve delivery of mass vaccination. Collaborative framework for research, development, manufacture, and deployment of next-generation health technologies using SatioRx intradermal patches for African Union member states.

4Institut Pasteur de Dakar
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-08-22
Description

Strategic partnership for research, development, manufacture, and distribution of next-generation healthcare technologies in Africa. Focuses on enabling low-cost access to vaccines and diagnostics to advance public health. Includes ebolavirus diagnostic immunoassay integration and broader pathogen detection expansion.

satiopatch.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Manufacturing partnership with Sapphiros for extreme volume manufacturing of diagnostics on their innovative proprietary process. Sapphiros is CLIA certified and operates nationally with comprehensive clinical and digital solutions for collection, testing, and reporting. Ensures low-cost and accessible platform technology for LMICs.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner in innovation with hands-on approach to bringing new technologies to life through careful development, cultivation, and incubation.

7Nowfuture
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner utilizing state-of-the-art technology to decode and interpret DNA insights most relevant to consumers.

satiopatch.com
8GoToKnow
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Direct-to-consumer sales channel that empowers customers through a portfolio of diagnostic and genomic tests.

satiopatch.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Drawbridge Health
TypeDirect peer
Description

Drawbridge Health's OneDraw device enables single-use, finger-click blood sample collection for lab testing, comparable to SatioDot/SatioDraw for at-home specimen collection feeding CLIA laboratories.

TypeDirect peer
Description

Tasso develops push-button dried blood spot and volumetric absorptive microsampling collection patches for at-home sample collection — a near-identical use case to Satio's SatioDot and SatioDraw platforms, serving CLIA labs and clinical research customers.

TypeDirect peer
Description

Yourbio commercializes touch-activated TAP blood-collection microneedle devices for decentralized clinical and at-home diagnostics, directly competing with Satio's whole-blood and DBS patch platforms.

TypeDirect peer
Description

Micron Biomedical develops dissolvable and seasonal-influenza microneedle patch products for vaccines and drug delivery — directly comparable to SatioRx's intradermal delivery value proposition for biologics and vaccines.

TypeDirect peer
Description

Vaxxas is commercializing high-density microarray microneedle patches for vaccine and therapeutic delivery, overlapping directly with SatioRx's microneedle drug-delivery platform and at-home administration thesis.

TypeBroad incumbent
Description

BD offers legacy microneedle injection products (e.g., Soluvia/MicroDose) and a broad medical-device portfolio including specimen collection and diagnostic solutions, making it an incumbent competitor across both SatioRx and the blood-collection patch businesses.

73M
TypeBroad incumbent
Description

3M's Drug Delivery Systems division produces hollow microneedle technologies and transdermal drug-delivery platforms, creating direct overlap with SatioRx across intradermal delivery for vaccines and biologics.

TypeBroad incumbent
Description

OraSure is an established player in dried blood spot collection (e.g., OraQuick, Intercept DBS) and at-home sample collection, making it a comparable incumbent serving clinical trials and decentralized testing — the same buyers Satio targets.

TypeEmerging player
Description

Raphas develops dissolving and coated microneedle patches for cosmetics, drugs and vaccines, representing an emerging competitor in the niche microneedle patch space that SatioRx is targeting.

TypeOthers
Description

Sapphiros is Satio's strategic manufacturing and CLIA-lab partner (KKR-backed), providing extreme-volume manufacturing for Satio's diagnostic patches and acting as a distribution channel into CLIA testing services.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Satio

Point-of-Care Medical Devicessatiopatch.com

Satio firmographics

Firmographics
Name
Satio
Legal name
satio, Inc.
Website
https://satiopatch.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Satio industry classification

Industry
Product category
Point-of-Care Medical Devices
NAICS
Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAO
DTx/SaMD Deployment, Integration & Reimbursement Enablement
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Patch-based diagnostics
  • Microneedle drug delivery
  • Blood collection devices
  • Intradermal delivery
  • Medical device patches

Where Satio is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Satio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Drug Delivery Patches (SatioRx): Sale of reusable applicators and disposable microneedle patches to pharmaceutical partners and healthcare providers. The reusable device with disposable components creates recurring consumable revenue.
  2. Diagnostic Patches (SatioDx): Sale of diagnostic patches incorporating lateral flow assays and biosensor technology to diagnostic and consumer healthcare companies.
  3. Blood Collection Patches (SatioDot/SatioDraw): Sale of blood collection patches to CLIA labs and diagnostic companies for laboratory developed tests. Revenue from patch sales to laboratory partners.
  4. Licensing and Partnership Revenue: Technology licensing to pharmaceutical companies for drug delivery applications and to diagnostic companies for platform integration. Strategic partnerships with BARDA and ARPA-H provide non-dilutive funding.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels4 records

Satio product offering

Product offering

Core offering

Satio develops patch-based platforms for at-home blood collection, point-of-care diagnostics, and intradermal drug and vaccine delivery. The portfolio comprises SatioRx (reusable applicator with disposable hollow microneedle arrays for remote-controlled drug delivery), SatioDx (adhesive patch integrating blood draw with lateral flow/biosensor readouts), SatioDot (dried blood spot collection patch for CLIA lab testing), and SatioDraw (whole blood collection patch of approximately 100uL for genomic and clinical tests).

Product overview

Satio develops a portfolio of four distinct patch-based platforms addressing diagnostics and drug delivery. SatioRx™ is a reusable drug delivery patch with microneedle arrays for intradermal/subcutaneous administration. SatioDx™ provides point-of-care blood draw and diagnosis with on-device results. SatioDot™ enables dried blood spot collection for lab-based testing. SatioDraw™ handles whole blood collection for CLIA laboratory testing. Together, these platforms enable decentralized healthcare with at-home diagnostics and drug delivery without needles or professional administration.

Differentiator

Problem solved

Functional benefit

Brands

  • SatioDot: Dried Blood Spot (DBS) collection patch for consumer-based sample collection for CLIA labs with laboratory developed tests.
  • SatioDraw
  • SatioDx
  • SatioRx

Products and services

  • SatioRx Reusable drug delivery platform with adhesive patch-based microneedle technology enabling stable and controlled intradermal or subcutaneous delivery of liquid medicines. Combines a motor-controlled applicator with disposable hollow non-dissolving microneedle elements, NFC connectivity, and telehealth integration for remote activation and monitoring, supporting 1mL to 5mL drug cartridges and viscosities up to 100cP.
  • SatioDx Consumer-based blood draw and diagnostic patch allowing users to collect blood and receive test results directly on the device. Available in Manual and Digital versions, with integrated lateral flow assays and biosensor technology, a lancet port with 130 microliter collection capacity, vacuum-assisted blood draw, and onboard result readout for multi-analyte screening.
  • SatioDot Dried blood spot (DBS) collection patch enabling simple, painless, and low-cost consumer-based self-collection for clinical laboratory testing with easy transport and storage, designed for CLIA labs running laboratory developed tests.
  • SatioDraw Whole blood collection patch allowing simple consumer-based collection of 100 microliters (range 50–150 microliters) for CLIA labs running laboratory developed tests, supporting diagnosis and whole genome sequencing without fingerstick or mess.

Quantifiable outcome

  • Increased payload delivery 2.5-5x compared to typical intradermal delivery
  • +5 more outcomes

Companies that use Satio

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Satio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Satio partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • NanowearcoreStrategic or Co-development Partner · 14 April 2025Strategic collaboration to integrate Nanowear's AI-based SimpleSense biomarker platform with Satio's blood draw diagnostics and drug delivery patches. Combines in vivo cardiometabolic biomarkers with in vitro blood diagnostics in a single digital app. Targets $55 billion biopharma clinical research market and $200 billion telehealth segment. First-of-its-kind combination of blood/genotype biomarkers with cardiometabolic physiological data.
  • BARDA DRIVecoreStrategic or Co-development Partner · 18 August 2023Contract partnership with Biomedical Advanced Research and Development Authority's Division of Research, Innovation and Ventures (DRIVe) to develop novel patch-based ebolavirus diagnostic. Combines Satio's patch-based blood collection with Institut Pasteur de Dakar's immunoassay. Goal to create low-cost, rapid diagnostic deployable by community health workers in remote settings.
  • INTACT SolutionsminorStrategic or Co-development Partner · 23 August 2022Partnership to jointly improve delivery of mass vaccination. Collaborative framework for research, development, manufacture, and deployment of next-generation health technologies using SatioRx intradermal patches for African Union member states.
  • Institut Pasteur de DakarcoreStrategic or Co-development Partner · 22 August 2022Strategic partnership for research, development, manufacture, and distribution of next-generation healthcare technologies in Africa. Focuses on enabling low-cost access to vaccines and diagnostics to advance public health. Includes ebolavirus diagnostic immunoassay integration and broader pathogen detection expansion.
  • Sapphiros / Sapphiros LaboratoriescoreStrategic or Co-development PartnerManufacturing partnership with Sapphiros for extreme volume manufacturing of diagnostics on their innovative proprietary process. Sapphiros is CLIA certified and operates nationally with comprehensive clinical and digital solutions for collection, testing, and reporting. Ensures low-cost and accessible platform technology for LMICs.
  • neoenta designminorStrategic or Co-development PartnerPartner in innovation with hands-on approach to bringing new technologies to life through careful development, cultivation, and incubation.
  • NowfutureminorStrategic or Co-development PartnerPartner utilizing state-of-the-art technology to decode and interpret DNA insights most relevant to consumers.
  • GoToKnowminorChannel Partner/ Reseller/ DistributorDirect-to-consumer sales channel that empowers customers through a portfolio of diagnostic and genomic tests.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Satio competitors and assessment

Company assessment

Direct peers

  • Drawbridge Health: Drawbridge Health's OneDraw device enables single-use, finger-click blood sample collection for lab testing, comparable to SatioDot/SatioDraw for at-home specimen collection feeding CLIA laboratories.
  • Tasso: Tasso develops push-button dried blood spot and volumetric absorptive microsampling collection patches for at-home sample collection — a near-identical use case to Satio's SatioDot and SatioDraw platforms, serving CLIA labs and clinical research customers.
  • Yourbio (formerly Seventh Sense Biosystems): Yourbio commercializes touch-activated TAP blood-collection microneedle devices for decentralized clinical and at-home diagnostics, directly competing with Satio's whole-blood and DBS patch platforms.
  • Micron Biomedical: Micron Biomedical develops dissolvable and seasonal-influenza microneedle patch products for vaccines and drug delivery — directly comparable to SatioRx's intradermal delivery value proposition for biologics and vaccines.
  • Vaxxas: Vaxxas is commercializing high-density microarray microneedle patches for vaccine and therapeutic delivery, overlapping directly with SatioRx's microneedle drug-delivery platform and at-home administration thesis.

Broad incumbents

  • BD (Becton, Dickinson and Company): BD offers legacy microneedle injection products (e.g., Soluvia/MicroDose) and a broad medical-device portfolio including specimen collection and diagnostic solutions, making it an incumbent competitor across both SatioRx and the blood-collection patch businesses.
  • 3M: 3M's Drug Delivery Systems division produces hollow microneedle technologies and transdermal drug-delivery platforms, creating direct overlap with SatioRx across intradermal delivery for vaccines and biologics.
  • OraSure Technologies: OraSure is an established player in dried blood spot collection (e.g., OraQuick, Intercept DBS) and at-home sample collection, making it a comparable incumbent serving clinical trials and decentralized testing — the same buyers Satio targets.

Emerging players

  • Raphas: Raphas develops dissolving and coated microneedle patches for cosmetics, drugs and vaccines, representing an emerging competitor in the niche microneedle patch space that SatioRx is targeting.

Others

  • Sapphiros Laboratories: Sapphiros is Satio's strategic manufacturing and CLIA-lab partner (KKR-backed), providing extreme-volume manufacturing for Satio's diagnostic patches and acting as a distribution channel into CLIA testing services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Satio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Satio leadership team

Management profile

Number of profiles

Profiles7 records

Satio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Satio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Satio

What does Satio do?

Satio develops patch-based platforms for at-home blood collection, point-of-care diagnostics, and intradermal drug and vaccine delivery. The portfolio comprises SatioRx (reusable applicator with disposable hollow microneedle arrays for remote-controlled drug delivery), SatioDx (adhesive patch integrating blood draw with lateral flow/biosensor readouts), SatioDot (dried blood spot collection patch for CLIA lab testing), and SatioDraw (whole blood collection patch of approximately 100uL for genomic and clinical tests).

Is Satio a public or private company?

Satio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Satio founded?

Satio was founded in 2021. It employs 11 to 50 people.

Where is Satio based?

Satio is headquartered in Boston, United States, in the North America region.

How does Satio make money?

Four revenue lines are on record. Drug Delivery Patches (SatioRx) is the primary driver. The others are diagnostic Patches (SatioDx), blood Collection Patches (SatioDot/SatioDraw) and licensing and Partnership Revenue.

Who are Satio's main competitors?

Direct peers on record are Drawbridge Health, Tasso, Yourbio (formerly Seventh Sense Biosystems), Micron Biomedical and Vaxxas. Broad incumbents are BD (Becton, Dickinson and Company), 3M and OraSure Technologies. Raphas is listed as an emerging player. Sapphiros Laboratories is listed as an others.

Does Satio have an API?

No public API is recorded for Satio.

What industry is Satio in?

Satio's product category is Point-of-Care Medical Devices. Its primary akta.pro industry code is HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints, with a secondary code of HLACANAO, DTx/SaMD Deployment, Integration & Reimbursement Enablement. Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AdvamedSatio, Nanowear announce partnership offering first, holistic, home-based in vivo- + in vitro diagnostics + drug deliverySatio and Nanowear have announced a partnership to combine their respective home-based diagnostic and drug delivery technologies into a holistic platform for precision therapeutics. This collaboration integrates Nanowear’s AI-based nanotechnology biomarker diagnostics with Satio’s blood draw systems and patches, targeting the biopharma and clinical research markets.SatiopatchCutting Edge At-Home MedTech and Digital Health Companies, Satio and Nanowear, to Collaborate on Accelerating Non-invasive Biomarkers, Diagnostics and Drug Delivery, Beyond the Remote Monitoring and DSatio and Nanowear announced a collaboration to advance home-based diagnostic and therapeutic care, integrating Nanowear’s AI biomarker platform with Satio’s blood draw and drug delivery patches. The partnership aims to merge blood and physiological data within a single platform to enable early diagnosis and personalized medicine, targeting a market valued at approximately $55 billion.PR NewswireCutting Edge At-Home MedTech and Digital Health Companies, Satio and Nanowear, to Collaborate on Accelerating Non-invasive Biomarkers, Diagnostics and Drug Delivery, Beyond the Remote Monitoring and DSatio and Nanowear announced a partnership to combine Nanowear's SimpleSense AI-based cardiometabolic diagnostics with Satio's blood draw and drug delivery patches. The collaboration aims to integrate in vitro and in vivo biomarkers for precision therapeutics, targeting a $55 billion biopharma market and a $200 billion home-based care market.PR NewswireSatio Receives Funding From ARPA-H to Develop SatioRx™ a Novel At-home, Remotely Controllable Transdermal Drug Delivery DeviceSatio received a $3.5 million SBIR contract from ARPA-H to develop SatioRx, a remotely controllable transdermal drug delivery device. The device uses disposable microneedles to deliver precise doses of FDA-approved liquid drugs, targeting at-home delivery and vaccine administration.SatiopatchSatio Receives Funding From ARPA-H to Develop SatioRx™ a Novel At-home, Remotely Controllable Transdermal Drug Delivery DeviceSatio has received a $3.5 million Small Business Innovation Research (SBIR) contract from the Advanced Research Projects Agency for Health (ARPA-H) to develop the SatioRx™, a novel at-home, remotely controllable transdermal drug delivery device. This device aims to provide precise drug delivery while addressing challenges related to treatment compliance in patients with chronic diseases and the convenience of vaccine delivery. The development of the SatioRx™ could enhance immunization efforts, especially in resource-limited settings.PR NewswireSatio partners with BARDA DRIVe to develop a novel patch-based ebolavirus diagnosticSatio, a Boston-based medical device company, announced a contract awarded by BARDA DRIVe to develop a single-use, rapid ebolavirus diagnostic combining Satio's patch-based blood collection device with Institut Pasteur de Dakar's immunoassay. The diagnostic will enable community health workers to deploy rapid testing in remote settings while limiting blood-borne pathogen exposure, with plans to expand detection to other blood-borne pathogens including HIV and syphilis. Satio has partnered with Sapphiros for low-cost manufacturing using extreme volume production processes to ensure accessibility in low- and middle-income countries.